Bio-Path Holdings, Inc. (BPTH)

USD 0.15

(0.0%)

Long Term Debt Summary of Bio-Path Holdings, Inc.

  • Bio-Path Holdings, Inc.'s latest annual long term debt in 2023 was 10 Thousand USD , down -91.15% from previous year.
  • Bio-Path Holdings, Inc.'s latest quarterly long term debt in 2024 Q2 was - USD , down 0.0% from previous quarter.
  • Bio-Path Holdings, Inc. reported annual long term debt of 113 Thousand USD in 2022, down -26.14% from previous year.
  • Bio-Path Holdings, Inc. reported annual long term debt of 153 Thousand USD in 2021, down -35.17% from previous year.
  • Bio-Path Holdings, Inc. reported quarterly long term debt of 3000.00 USD for 2024 Q1, down 0.0% from previous quarter.
  • Bio-Path Holdings, Inc. reported quarterly long term debt of 10 Thousand USD for 2023 Q4, down -60.0% from previous quarter.

Annual Long Term Debt Chart of Bio-Path Holdings, Inc. (2023 - 2004)

Historical Annual Long Term Debt of Bio-Path Holdings, Inc. (2023 - 2004)

Year Long Term Debt Long Term Debt Growth
2023 10 Thousand USD -91.15%
2022 113 Thousand USD -26.14%
2021 153 Thousand USD -35.17%
2020 236 Thousand USD -28.48%
2019 330 Thousand USD 0.0%
2018 - USD 0.0%
2017 - USD 0.0%
2016 - USD 0.0%
2015 - USD 0.0%
2014 - USD 0.0%
2013 - USD 0.0%
2012 - USD 0.0%
2011 - USD 0.0%
2010 - USD 0.0%
2009 - USD 0.0%
2008 - USD 0.0%
2007 - USD -100.0%
2006 78.7 Thousand USD 0.0%
2005 - USD -100.0%
2004 91.76 Thousand USD 0.0%

Peer Long Term Debt Comparison of Bio-Path Holdings, Inc.

Name Long Term Debt Long Term Debt Difference
America Great Health 1.12 Million USD 99.11%
Ampio Pharmaceuticals, Inc. - USD -Infinity%
Aridis Pharmaceuticals, Inc. 1.29 Million USD 99.226%
Biora Therapeutics, Inc. 43.73 Million USD 99.977%
Better Therapeutics, Inc. 10.34 Million USD 99.903%
Calithera Biosciences, Inc. 136 Thousand USD 92.647%
Comera Life Sciences Holdings, Inc. 120.3 Thousand USD 91.688%
Gene Biotherapeutics, Inc. - USD -Infinity%
eFFECTOR Therapeutics, Inc. - USD -Infinity%
Eloxx Pharmaceuticals, Inc. 8.69 Million USD 99.885%
Evelo Biosciences, Inc. 48.87 Million USD 99.98%
Evolutionary Genomics, Inc. 3.74 Million USD 99.733%
Finch Therapeutics Group, Inc. 28.4 Million USD 99.965%
Galera Therapeutics, Inc. 151.04 Million USD 99.993%
Innovation1 Biotech Inc. 218.99 Thousand USD 95.434%
Kiromic BioPharma, Inc. 911.5 Thousand USD 98.903%
Molecular Templates, Inc. 9.74 Million USD 99.897%
Navidea Biopharmaceuticals, Inc. 1.87 Million USD 99.466%
NexImmune, Inc. - USD -Infinity%
Orgenesis Inc. 19.06 Million USD 99.948%
Panbela Therapeutics, Inc. 4.19 Million USD 99.762%
Point of Care Nano-Technology, Inc. - USD -Infinity%
PaxMedica, Inc. Common Stock - USD -Infinity%
Scopus BioPharma Inc. - USD -Infinity%
Sorrento Therapeutics, Inc. 104.33 Million USD 99.99%
Statera Biopharma, Inc. 11.43 Million USD 99.913%
TRACON Pharmaceuticals, Inc. 732 Thousand USD 98.634%
Trevena, Inc. 35.23 Million USD 99.972%
Vaxxinity, Inc. 13.26 Million USD 99.925%
Vaccinex, Inc. 26 Thousand USD 61.538%
Vicapsys Life Sciences, Inc. - USD -Infinity%
Viracta Therapeutics, Inc. - USD -Infinity%
ZIVO Bioscience, Inc. - USD -Infinity%